Pharmaceuticals
News Category
VERAXA Biotech Names Christoph Erkel as Chief Scientific Officer to Lead BiTAC Platform Expansion
VERAXA Biotech AG appointed Christoph Erkel as CSO to advance its proprietary BiTAC platform for solid tumor cancer therapies, succeeding Rick Austin.
VERAXA Biotech Receives Positive Regulatory Feedback from Germany for Its BiTAC-TCE Platform
VERAXA Biotech AG announced it has received Scientific Advice from Germany's Paul-Ehrlich-Institute supporting the development strategy for its lead B...
VERAXA Biotech Receives Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform, Advancing Toward Clinical Development
VERAXA Biotech announced it received Scientific Advice from Germany's Paul-Ehrlich-Institute for its BiTAC-TCE platform, clarifying development strate...
Siegfried Appoints Eduardo Montanha as COO to Drive Operational Efficiency
Siegfried has appointed Eduardo Montanha as Chief Operating Officer, effective September 1, 2026, to strengthen supply performance and operational eff...
NextPlat Corp Acquires Florida Pharmacy for $1.5M to Expand PharmcoRx Rural Network
NextPlat Corp has agreed to acquire an independent pharmacy near Pensacola, Florida, for $1.5 million, aiming to expand its PharmcoRx retail footprint...
Onco-Innovations Completes Analytical Reference Standard Program for Lead Drug Candidate ONC010
Onco-Innovations Limited has finished its analytical reference standard program for the API supporting ONC010, strengthening CMC framework for clinica...
VERAXA Biotech Advances Lead BiTAC T-Cell Engager Program with Cell Line Development Partnership
VERAXA Biotech has initiated cell line development for its lead BiTAC T-cell engager program in partnership with ATUM, a key step toward clinical tria...
Sustained Release Polymers Market Set to Grow to USD 7.8 Billion by 2036, Driven by Chronic Disease Management and Advanced Drug Delivery
The global sustained release polymers market is projected to reach USD 7.8 billion by 2036, growing at a 7.4% CAGR, as pharmaceutical companies increa...
VERAXA Biotech Advances BiTAC Pipeline, Seeks Partnerships for Non-Core Assets
VERAXA Biotech AG updates on its BiTAC platform progress and partnership strategy, prioritizing T-cell engager programs while monetizing non-core asse...
VERAXA Biotech Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program
VERAXA Biotech has started cell line development for its lead BiTAC T-cell engager program through a collaboration with ATUM, advancing its promising ...
VERAXA Biotech AG Positioned to Benefit from Strong Antibody Therapeutics Deal Activity
Pharmaceutical companies are increasingly committing substantial capital to preclinical antibody platforms, creating potential value for VERAXA Biotec...
Ace Therapeutics Launches Comprehensive Preclinical Analgesic Drug Development Services
Ace Therapeutics announces a full-spectrum preclinical pain research platform with diverse in vivo models and end-to-end services to accelerate analge...
Medios AG Closes Aschaffenburg Facility to Optimize Manufacturing Network Amid Margin Pressure
Medios AG is closing its Aschaffenburg plant and consolidating production to improve profitability, affecting 32 employees, as regulatory price adjust...
Helus Pharma Reports Fiscal 2026 Results, Phase 3 Depression Trial Enrollment Surpasses 88%
Helus Pharma announced fiscal 2026 financial results and progress in its Phase 3 trial for major depressive disorder, with topline data expected in Q4...
Voyageur Pharmaceuticals Hires Fluor for Feasibility Studies on Iodine Production and Contrast Drug Manufacturing Facility
Voyageur Pharmaceuticals has engaged Fluor Corporation to conduct feasibility studies for an iodine extraction facility in Oklahoma and an integrated ...
Knight Therapeutics Repays $60 Million Credit Facility Used for Paladin Acquisition
Knight Therapeutics repaid the full $60 million drawn from its credit facility to fund the Paladin acquisition, using operational cash flow, while mai...
Voyageur Pharmaceuticals Evaluates Three U.S. Sites for Integrated Contrast Media Manufacturing Facility
Voyageur Pharmaceuticals is assessing potential locations in Oklahoma and Texas for a vertically integrated iodine and barium contrast media plant, ai...
Telomir Pharmaceuticals Publishes Preclinical Data Showing Telomir-Zn Improves Insulin Sensitivity in Type 2 Diabetes Model
Telomir Pharmaceuticals announced the publication of preclinical data in Biomedicine & Pharmacotherapy demonstrating that its lead candidate, Telomir-...
Helix BioPharma Reports Reduced Losses and Advances Financing for L-DOS47 Development
Helix BioPharma Corp. announced improved financial results for the nine months ended April 30, 2026, with a net loss of $2.374 million compared to $4....
Tonix Pharmaceuticals to Present at BTIG Infectious Disease Day 2026
Tonix Pharmaceuticals announced its participation in BTIG Infectious Disease Day 2026, highlighting its immunology pipeline including Lyme disease pro...
Helus Pharma CMO to Present at H.C. Wainwright Neuro Perspectives Conference
Helus Pharma announced that its Chief Medical Officer will participate in a fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid ...
Onco-Innovations Advances Manufacturing Process for Cancer Drug Candidate ONC010
Onco-Innovations Limited has initiated process development and intermediate scale-up for ONC010's active ingredient, marking a key step toward IND-ena...
Voyageur Pharmaceuticals Submits Multi-Year Permit Application for Frances Creek Barite Project
Voyageur Pharmaceuticals has submitted a multi-year exploration permit application for its Frances Creek barite project in British Columbia, aiming to...
Sharon Polsky's 'Weight Loss Decoded' Offers Straight-Talking Guide to GLP-1 Medications Amid Rising Demand
Sharon Polsky releases a new book that cuts through hype and misinformation to provide clear, science-based guidance on GLP-1 weight loss medications,...
Carmed Pharmaceuticals Highlights Second Peer-Reviewed Study of Its Formulations in 2026
Carmed Pharmaceuticals announces a second peer-reviewed study in 2026 on its Vacrol® and S-Mix® formulations, published in Antioxidants, underscoring ...
Amerigo Scientific Launches Extensive Small Molecule Portfolio to Advance Stem Cell Research and Therapy Manufacturing
Amerigo Scientific introduces a comprehensive range of research-grade and GMP-grade small molecules designed to support stem cell research, regenerati...
CNS Pharmaceuticals Highlights Oversubscribed $22.5 Million Financing, Growth Strategy in Investor Presentation
CNS Pharmaceuticals discusses its oversubscribed $22.5 million financing and strategic reset, indicating strong institutional investor confidence and ...
Tonix Pharmaceuticals Expands TONMYA Coverage to 52 Million Commercial Lives
Tonix Pharmaceuticals announced a coverage agreement with a second major group purchasing organization, expanding TONMYA's commercial access to 52 mil...
Oncotelic Therapeutics to Highlight AI Drug Discovery Platform at Qdrant Vector Space Day 2026
Oncotelic Therapeutics will showcase its PDAOAI platform, built on Qdrant infrastructure, which accelerated two drug candidates from concept to IND fi...
Redwood AI Corp. Positions AI Platform for Drug Discovery and Chemical Intelligence Across Multiple Markets
Redwood AI Corp. is developing a proprietary AI platform for drug discovery, synthesis planning, and chemical analysis, targeting pharmaceutical, defe...
Voyageur Pharmaceuticals Closes $5 Million Private Placement for Barium and Iodine Contrast Development
Voyageur Pharmaceuticals raised $5 million through a non-brokered private placement to fund FDA licensing and project development for its barium and i...
Psychiatry's Historical Resistance to Antidepressant Warnings Threatens New Deprescribing Plan, CCHR Warns
The Citizens Commission on Human Rights warns that organized psychiatry's pattern of downplaying antidepressant risks and opposing warnings could unde...
Stonegate Capital Updates Coverage on Cingulate After FDA CMC Request, Highlights Strong Cash Position
Stonegate Capital Partners updated coverage on Cingulate Inc. following an FDA Complete Response Letter focused on CMC issues, shifting the timeline b...
Quantum BioPharma Builds Diversified Pipeline Targeting Neurological and Wellness Markets
Quantum BioPharma is advancing a novel multiple sclerosis therapy through its subsidiary Lucid Psycheceuticals and expanding into the alcohol health m...
New Pill Shows Promise in Doubling Survival for Pancreatic Cancer Patients
Revolution Medicines' new pill daraxonrasib targets KRAS mutations and has reportedly doubled survival in early trials, offering hope against a notori...
Onco-Innovations Achieves Kilogram-Scale Manufacturing Milestone for ONC010 Cancer Therapy
Onco-Innovations Limited announced successful kilogram-scale production of the B4 precursor for its lead PNKP inhibitor ONC010, advancing toward clini...
GeoVax CEO Says Pharma Acquisitions Signal Renewed Strategic Focus on Vaccine Innovation and Health Security
GeoVax Labs' CEO David Dodd comments on recent pharmaceutical acquisitions by Eli Lilly, interpreting them as a strategic shift toward viewing vaccine...
Quantum BioPharma Highlights Lucid-MS and unbuzzd™ Growth Opportunities on BioMedWire Podcast
Quantum BioPharma's co-founder discusses the company's promising MS drug candidate Lucid-MS and commercial alcohol metabolism product unbuzzd™, highli...
Oncotelic Therapeutics Advances Nanoparticle Drug Delivery Platforms Amid Industry Shift
Oncotelic Therapeutics is highlighted in a BioMedWire editorial for its Sapu003 program and Deciparticle platform, reflecting a broader biotech trend ...
Quantum BioPharma Highlights Lucid-MS and unbuzzd(TM) Growth on BioMedWire Podcast
Quantum BioPharma's lead drug candidate Lucid-MS targets mobility loss in multiple sclerosis by addressing nerve damage, while its commercial product ...
Helus Pharma to Present at Jefferies Global Healthcare Conference
Helus Pharma announced its participation in the Jefferies Global Healthcare Conference, highlighting its clinical-stage development of novel serotoner...
Oncotelic Therapeutics Maintains $388M JV Valuation Amid Biotech Market Turbulence
Oncotelic Therapeutics Inc. reported a stable fair value of $388 million for its 45% stake in GMP Biotechnology, highlighting resilience in a volatile...
Oncotelic Therapeutics Maintains $388M JV Valuation Amid Biotech Volatility
Oncotelic Therapeutics (OTCQB: OTLC) reported its first-quarter 2026 financial results, maintaining the fair value of its 45% stake in GMP Biotechnolo...
Tonix Pharmaceuticals Presents Real-World Data Showing Widespread Opioid Use Among Fibromyalgia Patients
New data presented by Tonix Pharmaceuticals reveals that despite guidelines discouraging opioid use, nearly 40% of fibromyalgia patients are prescribe...
LakeShore Biopharma Calls EGM to Vote on Merger That Would Take Company Private
LakeShore Biopharma announced an extraordinary general meeting on June 19, 2026, to vote on a merger agreement that would make the company privately h...
Tonix Pharmaceuticals Publishes Phase 1 TNX-1500 Data in Journal of Clinical Immunology, Supporting Advancement into Phase 2 Studies
Tonix Pharmaceuticals announced publication of positive Phase 1 data for its anti-CD40L monoclonal antibody TNX-1500, showing favorable safety and tol...
Visory Health Promotes Alexandra Robertson and Brittney Tierce to C-Suite Roles Amid Growth
Visory Health has promoted Alexandra Robertson to Chief Growth Officer and Brittney Tierce to Chief Technology Officer, reflecting the company's rapid...
NanoViricides Highlights NV-387 as Potential Treatment for Bundibugyo Ebola Outbreak
NanoViricides announces that its broad-spectrum antiviral candidate NV-387 could be evaluated for the Bundibugyo Ebola outbreak, offering potential ad...